Sarepta Therapeutics (SRPT) EBITDA (2010 - 2026)

Sarepta Therapeutics' EBITDA history runs 17 years deep, the most recent figure standing at $358.4 million for Q1 2026.

• In Q1 2026, EBITDA rose 219.32% year-over-year to $358.4 million; the TTM figure through Mar 2026 stood at -$41.0 million (up 65.05% YoY), while the FY2025 annual figure was -$699.8 million, down 420.88% from the prior year.
• EBITDA for Q1 2026 stood at $358.4 million, up from -$411.6 million in the prior quarter.
• The five-year high for EBITDA was $358.4 million in Q1 2026, with the low at -$411.6 million in Q4 2025.
• The 5-year median for EBITDA is -$86.9 million (2022), against an average of -$54.5 million.
• Peak annual rise in EBITDA reached 16587.45% in 2025, while the deepest fall reached 960.58% in 2025.
• Sarepta Therapeutics' EBITDA stood at -$106.8 million in 2022, then surged by 123.05% to $24.6 million in 2023, then soared by 556.57% to $161.7 million in 2024, then sank by 354.56% to -$411.6 million in 2025, then surged by 187.09% to $358.4 million in 2026.
• Business Quant data shows SRPT's EBITDA at $358.4 million in Q1 2026, -$411.6 million in Q4 2025, and -$103.4 million in Q3 2025.